Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15


Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers.

Henninger C, Fritz G.

Cell Death Dis. 2017 Jan 19;8(1):e2564. doi: 10.1038/cddis.2016.418. Review.


A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.

Spallarossa P, Maurea N, Cadeddu C, Madonna R, Mele D, Monte I, Novo G, Pagliaro P, Pepe A, Tocchetti CG, Zito C, Mercuro G.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S84-92. doi: 10.2459/JCM.0000000000000381.


Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice.

Pillai VB, Bindu S, Sharp W, Fang YH, Kim G, Gupta M, Samant S, Gupta MP.

Am J Physiol Heart Circ Physiol. 2016 Apr 15;310(8):H962-72. doi: 10.1152/ajpheart.00832.2015. Epub 2016 Feb 12.


Non-pegylated liposomal Doxorubicin-cyclophosphamide in sequential regimens with taxanes as neoadjuvant chemotherapy in breast cancer patients.

Vici P, Pizzuti L, Gamucci T, Sergi D, Conti F, Zampa G, Del Medico P, De Vita R, Pozzi M, Botti C, Di Filippo S, Tomao F, Sperduti I, Di Lauro L.

J Cancer. 2014 Apr 25;5(6):398-405. doi: 10.7150/jca.9132. eCollection 2014.


Cardiotoxicity and oncological treatments.

Schlitt A, Jordan K, Vordermark D, Schwamborn J, Langer T, Thomssen C.

Dtsch Arztebl Int. 2014 Mar 7;111(10):161-8. doi: 10.3238/arztebl.2014.0161. Review.


Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation.

Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Naga Prasad SV, Mutharasan RK, Naik TJ, Ardehali H.

J Clin Invest. 2014 Feb;124(2):617-30. doi: 10.1172/JCI72931. Epub 2014 Jan 2.


Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.

Vavrova A, Jansova H, Mackova E, Machacek M, Haskova P, Tichotova L, Sterba M, Simunek T.

PLoS One. 2013 Oct 7;8(10):e76676. doi: 10.1371/journal.pone.0076676. eCollection 2013.


Effects of MnDPDP and ICRF-187 on Doxorubicin-Induced Cardiotoxicity and Anticancer Activity.

Kurz T, Grant D, Andersson RG, Towart R, De Cesare M, Karlsson JO.

Transl Oncol. 2012 Aug;5(4):252-9. Epub 2012 Aug 1.


Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.

Stěrba M, Popelová O, Vávrová A, Jirkovský E, Kovaříková P, Geršl V, Simůnek T.

Antioxid Redox Signal. 2013 Mar 10;18(8):899-929. doi: 10.1089/ars.2012.4795. Epub 2012 Oct 12. Review.


Anthracyclines: a cornerstone in the management of non-Hodgkin's lymphoma.

Luminari S, Montanini A, Federico M.

Hematol Rep. 2011 Oct 28;3(3s):e4. doi: 10.4081/hr.2011.s3.e4.


Dexrazoxane ameliorates doxorubicin-induced injury in mouse ovarian cells.

Roti Roti EC, Salih SM.

Biol Reprod. 2012 Mar 30;86(3):96. doi: 10.1095/biolreprod.111.097030. Print 2012 Mar.


Synthetic and natural iron chelators: therapeutic potential and clinical use.

Hatcher HC, Singh RN, Torti FM, Torti SV.

Future Med Chem. 2009 Dec;1(9):1643-70. doi: 10.4155/fmc.09.121. Review.


Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?

Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC.

Prog Cardiovasc Dis. 2010 Sep-Oct;53(2):105-13. doi: 10.1016/j.pcad.2010.06.007. Review.


Anthracycline cardiotoxicity: from bench to bedside.

Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB.

J Clin Oncol. 2008 Aug 1;26(22):3777-84. doi: 10.1200/JCO.2007.14.9401.


Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone.

Simůnek T, Sterba M, Popelová O, Kaiserová H, Adamcová M, Hroch M, Hasková P, Ponka P, Gersl V.

Br J Pharmacol. 2008 Sep;155(1):138-48. doi: 10.1038/bjp.2008.236. Epub 2008 Jun 9.

Supplemental Content

Support Center